2018
DOI: 10.1200/jco.2018.36.15_suppl.e15048
|View full text |Cite
|
Sign up to set email alerts
|

Engineered t cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
38
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 18 publications
(40 citation statements)
references
References 45 publications
(103 reference statements)
2
38
0
Order By: Relevance
“…Although E7 11-20 has been identified as an immunodominant HLA-A Ã 0201 epitope (10), the E7 [11][12][13][14][15][16][17][18][19] peptide is also naturally processed and presented on cancer cells (11). Thus, it is significant that the two TCRs identified and tested from CUE-101 expanded CD8 þ T cells were able to recognize both the E7 11-20 and E7 [11][12][13][14][15][16][17][18][19] peptides, suggesting that if only one of these peptides is processed and presented in a given patient CUE-101 will expand a relevant CTL population. Therefore, CUE-101 has the potential to harness a diverse, native T-cell repertoire to mount an effective antitumor immune response while avoiding systemic activation of the immune system.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Although E7 11-20 has been identified as an immunodominant HLA-A Ã 0201 epitope (10), the E7 [11][12][13][14][15][16][17][18][19] peptide is also naturally processed and presented on cancer cells (11). Thus, it is significant that the two TCRs identified and tested from CUE-101 expanded CD8 þ T cells were able to recognize both the E7 11-20 and E7 [11][12][13][14][15][16][17][18][19] peptides, suggesting that if only one of these peptides is processed and presented in a given patient CUE-101 will expand a relevant CTL population. Therefore, CUE-101 has the potential to harness a diverse, native T-cell repertoire to mount an effective antitumor immune response while avoiding systemic activation of the immune system.…”
Section: Discussionmentioning
confidence: 99%
“…A total of 2 to 4 Â 10 6 human PBMCs expanded with CUE-101 or peptide were pretreated with Brefeldin A (BFA) and Monensin (Thermofisher), plated in a 24-well plate, and stimulated at a 1:1 ratio with T2 cells (ATCC) that had been loaded with 5 mg/mL of E7 [11][12][13][14][15][16][17][18][19][20] (YMLDLQPETT) or HIV-1 p17 Gag 77-85 (SLYNTVATL; SL9) peptide for 2 hours and washed twice. Alternatively, 2 Â 10 6 murine cells were plated in a 96-well U-bottom plate and restimulated in CTL Test Medium containing 1% Glutamax by combining E7 49-57 peptide (RAHYNIVTF; 10 mg/mL) with BFA and Monensin diluted per the manufacturer's instructions.…”
Section: Intracellular Cytokine Stainingmentioning
confidence: 99%
See 1 more Smart Citation
“…Approximately 15-20% of all cancers worldwide are associated with infection, the majority associated with viral infection 35 , whilst bacteria and multicellular parasites are responsible for only a fraction of these infection-related cancers 46 .…”
Section: Viral Infections and Virus-associated Malignanciesmentioning
confidence: 99%
“…Identification and sequencing of TCRs able to recognise epitopes expressed by human tumours together with improvements in TCR gene transfer technology have allowed for rapid redirection of T cells and targeting of a variety of tumour antigens, including gp100 28 , p53 29 , carcinoembryonic antigen (CEA) 28 , cancer-testis antigen (CTA) family members (e.g. NY-ESO-1 30 , MAGE-A3 31 , MAGE-A4 32 and MAGE-A10 33 ), and viral protein family members 34,35 .…”
mentioning
confidence: 99%